Fisher Wallace Laboratories
Other, Brooklyn, New York, United States, 1-10 Employees
Phone Number: 21********
Who is FISHER WALLACE LABORATORIES
Fisher Wallace Labs is the leading developer of wearable brain stimulation technology for the treatment of depression and other neuropsychiatric and cognitive disorders. The commercial ve...
Read More
- Headquarters: Brooklyn, New York, United States
- Date Founded: 2007
- Employees: 1-10
- Revenue: $5 Million to $10 Million
- Active Tech Stack: See technologies
- CEO: Kelly Roman
Does something look wrong? Fix it. | View contact records from FISHER WALLACE LABORATORIES
Fisher Wallace Laboratories Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Fisher Wallace Laboratories
Answer: Fisher Wallace Laboratories's headquarters are located at Brooklyn, New York, United States
Answer: Fisher Wallace Laboratories's phone number is 21********
Answer: Fisher Wallace Laboratories's official website is https://fisherwallace.com
Answer: Fisher Wallace Laboratories's revenue is $5 Million to $10 Million
Answer: Fisher Wallace Laboratories's SIC: 5047
Answer: Fisher Wallace Laboratories's NAICS: 541715
Answer: Fisher Wallace Laboratories has 1-10 employees
Answer: Fisher Wallace Laboratories is in Other
Answer: Fisher Wallace Laboratories contact info: Phone number: 21******** Website: https://fisherwallace.com
Answer: Fisher Wallace Labs is the leading developer of wearable brain stimulation technology for the treatment of depression and other neuropsychiatric and cognitive disorders. The commercial version of our Version 2.0 technology, called OAK, was designed in collaboration with the teams behind Beats and Nest, and is intended to become the first superdevice for mental health that achieves smartphone scale. We completed a 255-subject, triple-blind, randomized, sham-controlled trial that demonstrated rapid effectiveness in treating depression (highly effective in the first seven days) without causing serious side effects; results will soon be published by The Journal of Clinical Psychiatry. We are now collaborating with world-class researcher partners, including Massachusetts General Hospital, to conduct a final study for FDA approval. Building towards a future in which our technology is approved to treat a universe of conditions, we recently completed a Generalized Anxiety Disorder study in collaboration with the Seattle Police Department, and are currently applying for a $5M Alzheimers research award. Under temporary FDA clearance, our Version 1.0 (proof-of-concept) technology was distributed to over 90,000 patients via 14,000 prescribers, generating $40 million in revenue, and obtained Medicaid reimbursement (MaineCare).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month